GSK, RSV and Shingles
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses compared with separate administration of the vaccines.
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK Builds Combo Case for RSV, Shingles Shots With Phase III Data
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients and potentially bolster GSK’s faltering sales for both vaccines.
GSK pursues co-administration of RSV and shingles vaccines
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new hope.
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over 50 years of age, met the main goal of the study. The co-administration will help in "reducing the number of visits to the healthcare offices and pharmacies and ultimately help to get ahead of RSV and shingles,
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
What’s the RSV Vaccine? Here’s What You Need to Know About the UK Rollout
Starting in September, the UK’s new RSV vaccine program will offer protection across all age groups — find out what this ...
The American Journal of Managed Care3d
New RSV Vaccine Is Likely Cost-Effective for Older Adults, Study Finds
Respiratory syncytial virus (RSV) vaccination in adults aged 60 years and older may be cost-effective in preventing illness, ...
WGAL8d
Pulmonologist talks about RSV: Symptoms, who's most at risk, effectiveness of vaccine
A UPMC pulmonologist talks about the symptoms, explains who is most at risk for a severe infection, and tells us how ...
KOAT Albuquerque on MSN10d
New guidelines for who should take RSV vaccine
It's been more than a year since the Food and Drug Administration approved the first vaccine to treat RSV. Since then, newly ...
COVID-19, flu and RSV shots: Do I really need all three?
All flu vaccines for the 2024-25 season will be trivalent, meaning they protect against three different strains of influenza: ...
RSV vaccine rolled out in Jersey to combat respiratory illnesses
The Respiratory Syncytial Virus (RSV) vaccine will be rolled out to some older islanders as well as pregnant women. | ITV ...
After years of advocacy by a pediatrician, all Nunavut babies to get RSV immunization
The Nunavut government says it will provide immunization against respiratory syncytial virus to all infants in the territory ...
ABRYSVO™: Pfizer Canada's Newly Publicly Funded Vaccine a Step Towards National RSV Prevention in Older Adults
Pfizer Canada ULC announced that ABRYSVO™ has been selected as the publicly-funded vaccine for the prevention of Respiratory ...